Last reviewed · How we verify
NCT03075254
Central Mechanisms of Chronic Pain and Fatigue Subtitle: Functional Imaging of Brain and Spinal Cord
trial testing A Peltier for Sensory testing in Chronic Fatigue Syndrome in 197 participants. Completed in 29 October 2024.
29 October 2024
Quick facts
| Lead sponsor | University of Florida |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 197 |
| Start date | 15 March 2017 |
| Primary completion | 29 October 2024 |
| Estimated completion | 29 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- A Peltier for Sensory testing
- functional magnetic resonance imaging for Brain Neuroimaging
- fMRI for Spinal Cord Neuroimaging
Conditions studied
- Chronic Fatigue Syndrome — all drugs for Chronic Fatigue Syndrome →
- Fibromyalgia — all drugs for Fibromyalgia →
Sponsor
University of Florida
Who can join
Adults 18 to 70, any sex, with Chronic Fatigue Syndrome or Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic pain and fatigue are characterized by peripheral and central mechanisms including low pain thresholds, temporal summation, peripheral and central sensitization. This application will focus on central factors of chronic pain and fatigue. Functional brain imaging will be used to characterized brain and spinal cord abnormalities that contribute to the mechanisms of these disorders.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03075254
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Fatigue Syndrome
Currently open trials in the same condition.
- NCT07009691 — Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS · NA · recruiting
- NCT06585254 — tVNS in Long COVID-19 · NA · recruiting
- NCT05741112 — The Long COVID-19 Wearable Device Study · NA · recruiting
- NCT05967052 — Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitati · Phase 2 · recruiting
- NCT05525598 — Internet-based Treatment for Patients Suffering From Severe Functional Somatic Disorders · NA · recruiting
Other University of Florida trials
Trials by the same sponsor.
- NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
- NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
- NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
- NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
- NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03075254 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Florida
- Last refreshed: 27 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03075254.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing